143 related articles for article (PubMed ID: 38625984)
1. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.
Nikiforow S; Whangbo JS; Reshef R; Tsai DE; Bunin N; Abu-Arja R; Mahadeo KM; Weng WK; Van Besien K; Loeb D; Nasta SD; Nemecek ER; Zhao W; Sun Y; Galderisi F; Wahlstrom J; Mehta A; Gamelin L; Dinavahi R; Prockop S
Blood Adv; 2024 Jun; 8(12):3001-3012. PubMed ID: 38625984
[TBL] [Abstract][Full Text] [Related]
2. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
Mahadeo KM; Baiocchi R; Beitinjaneh A; Chaganti S; Choquet S; Dierickx D; Dinavahi R; Duan X; Gamelin L; Ghobadi A; Guzman-Becerra N; Joshi M; Mehta A; Navarro WH; Nikiforow S; O'Reilly RJ; Reshef R; Ruiz F; Spindler T; Prockop S
Lancet Oncol; 2024 Mar; 25(3):376-387. PubMed ID: 38309282
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.
Barlev A; Zimmermann H; Guzman-Becerra N; Mehta A; Xing B; Macabeo B; Thivolet M; Brookhart MA
J Med Econ; 2024; 27(1):789-795. PubMed ID: 38727527
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
[TBL] [Abstract][Full Text] [Related]
5. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
[TBL] [Abstract][Full Text] [Related]
6. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Romero S; Montoro J; Guinot M; Almenar L; Andreu R; Balaguer A; Beneyto I; Espí J; Gómez-Codina J; Iacoboni G; Jarque I; López-Andújar R; Mayordomo-Aranda E; Montalar J; Pastor A; Pastor M; Piñana JL; Rojas-Ferrer N; Sánchez-Lázaro I; Sandoval J; Sanz G; Sanz MÁ; Solé A; Sanz J
Leuk Lymphoma; 2019 Jan; 60(1):142-150. PubMed ID: 29966464
[TBL] [Abstract][Full Text] [Related]
7. Tabelecleucel: First Approval.
Keam SJ
Mol Diagn Ther; 2023 May; 27(3):425-431. PubMed ID: 37016096
[TBL] [Abstract][Full Text] [Related]
8. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy.
Socié G; Barba P; Barlev A; Sanz J; García-Cadenas I; Chevallier P; Fagioli F; Guzman-Becerra N; Kumar D; Ljungman P; Pigneux A; Sadetsky N; Yáñez San Segundo L; Shadman M; Storek J; Thirumalai D; Xing B; Mohty M
Bone Marrow Transplant; 2024 Jan; 59(1):52-58. PubMed ID: 37865719
[TBL] [Abstract][Full Text] [Related]
9. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.
Prockop S; Doubrovina E; Suser S; Heller G; Barker J; Dahi P; Perales MA; Papadopoulos E; Sauter C; Castro-Malaspina H; Boulad F; Curran KJ; Giralt S; Gyurkocza B; Hsu KC; Jakubowski A; Hanash AM; Kernan NA; Kobos R; Koehne G; Landau H; Ponce D; Spitzer B; Young JW; Behr G; Dunphy M; Haque S; Teruya-Feldstein J; Arcila M; Moung C; Hsu S; Hasan A; O'Reilly RJ
J Clin Invest; 2020 Feb; 130(2):733-747. PubMed ID: 31689242
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
Lindsay J; Othman J; Yong MK; Ritchie D; Chee L; Tay K; Tio SY; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Greenwood M; Pergam SA; Liu C; Slavin MA
Transpl Infect Dis; 2021 Oct; 23(5):e13719. PubMed ID: 34453768
[TBL] [Abstract][Full Text] [Related]
11. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD;
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.
Holman CJ; Karger AB; Mullan BD; Brundage RC; Balfour HH
Clin Transplant; 2012; 26(5):741-7. PubMed ID: 22385033
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes.
Lindsay J; Othman J; Heldman MR; Slavin MA
Curr Opin Infect Dis; 2021 Dec; 34(6):635-645. PubMed ID: 34751183
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
Chen DB; Song QJ; Chen YX; Chen YH; Shen DH
Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
[TBL] [Abstract][Full Text] [Related]
18. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
[TBL] [Abstract][Full Text] [Related]
19. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
Naik S; Riches M; Hari P; Kim S; Chen M; Bachier C; Shaughnessy P; Hill J; Ljungman P; Battiwalla M; Chhabra S; Daly A; Storek J; Ustun C; Diaz MA; Cerny J; Beitinjaneh A; Yared J; Brown V; Page K; Dahi PB; Ganguly S; Seo S; Chao N; Freytes CO; Saad A; Savani BN; Woo Ahn K; Boeckh M; Heslop HE; Lazarus HM; Auletta JJ; Kamble RT
Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099
[TBL] [Abstract][Full Text] [Related]
20. Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation.
Marjanska A; Styczynski J
Expert Opin Biol Ther; 2023; 23(6):539-552. PubMed ID: 36971380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
